berdazimer 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
polymers 5860 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • berdazimer
  • berdazimer sodium
  • zelsuvmi
  • SB206
  • NVN1000
Berdazimer is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 5, 2024 FDA Ligand Pharmaceuticals (LNHC)

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D06BB13 DERMATOLOGICALS
ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
CHEMOTHERAPEUTICS FOR TOPICAL USE
Antivirals
CHEBI has role CHEBI:35718 antifungal agent

Related Drugs by ATC class:

D06BB Antivirals 11 drugs
acyclovirdocosanoledoxudineibacitabineidoxuridineimiquimodinosinepenciclovirpodophyllotoxinsinecatechinstromantadine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection caused by Molluscum contagiosum indication 40070004 DOID:8867




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 9737561 Aug. 20, 2030 METHOD OF TREATING SKIN AILMENT WITH NITRIC OXIDE RELEASING MACROMOLECULES AND HYDROPHILIC GEL
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 9289442 July 3, 2032 METHOD OF APPLICATION OF TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT DERMATOLOGICAL CONDITION
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 9855211 Feb. 27, 2034 METHOD OF APPLYING RELEASED NITRIC OXIDE TO SKIN FROM COMBINATION INCLUDING ANHYDROUS ALCOHOL GEL
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 9855211 Feb. 27, 2034 METHOD OF INCREASING RELEASE OF NITRIC OXIDE FROM ANHYDROUS ALCOHOL GEL
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10258564 Nov. 22, 2034 METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10258564 Nov. 22, 2034 METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES A NITRIC OXIDE RELEASING COMPOUND
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10258564 Nov. 22, 2034 METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES WATER
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10322081 July 10, 2035 METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING API IN A COMBINATION TOPICAL COMPOSITION
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10322081 July 10, 2035 METHOD OF PREVENTING AND/OR REDUCING APPEARANCE AND/OR SIZE OF MALIGNANT LESION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10322081 July 10, 2035 METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10322081 July 10, 2035 METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10736839 July 10, 2035 METHOD OF TREATING AND/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A NITRIC OXIDE RELEASING TOPICAL COMPOSITION
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10736839 July 10, 2035 METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION WITH A TOPICAL NITRIC OXIDE RELEASING COMPONENT
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 10736839 July 10, 2035 METHOD OF TREATING, PREVENTING, OR REDUCING LESIONS CAUSED BY MOLLUSCUM CONTAGIOSUM
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 11040006 July 10, 2035 METHOD OF TREATING AND/OR PREVENTING VIRAL INFECTION USING A NITRIC OXIDE RELEASING ACTIVE INGREDIENT
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL 11723858 July 10, 2035 METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING ACTIVE PHARMACEUTICAL INGREDIENT TO TREAT AND/OR PREVENT VIRAL INFECTION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10.3% BASE ZELSUVMI LNHC N217424 Jan. 5, 2024 RX GEL TOPICAL Jan. 5, 2029 NEW CHEMICAL ENTITY

Bioactivity Summary:

None

External reference:

IDSource
4044017 VANDF
C5884357 UMLSCUI
CHEMBL4298064 ChEMBL_ID
1846565-00-1 SECONDARY_CAS_RN
10351 INN_ID
2710434 RXNORM
C000709171 MESH_SUPPLEMENTAL_RECORD_UI
D12758 KEGG_DRUG
ORT9SID4QY UNII
377491 MMSL
42455 MMSL
019653 NDDF
019655 NDDF
CHEBI:757487 CHEBI

Pharmaceutical products:

None